HMGB1 and neoplasm: When acting on tumor cells, they can reduce tumor cell viability, at the same time trigger ROS-related endoplasmic reticulum stress response, induce activation of the PERK signaling pathway, and phosphorylate EIF2α and ICD-related DAMPs, including CRT exposure and release of HMGB1 and type I interferon.